Is Thoracic Radiotherapy an Absolute Contraindication for Treatment of Lung Cancer Patients With Interstitial Lung Disease? A Systematic Review
Affiliation
Department of Oncology, Apollo Multi-speciality Hospitals, Kolkata, India. Electronic address: mesh.vicky@gmail.com. Department of Clinical Oncology, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK. Department of Clinical Oncology, Arden Cancer Centre, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK. Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Clinical Oncology, Christie NHS Foundation Trust, Manchester, UK. Department of Pulmonary Medicine, Apollo Multi-speciality Hospitals, Kolkata, India.Issue Date
2022
Metadata
Show full item recordAbstract
Thoracic radiotherapy decisions in patients with interstitial lung disease (ILD) are complex due to concerns about severe or even fatal radiation pneumonitis. This systematic review analysed the published evidence regarding the incidence of radiation pneumonitis and mortality after thoracic radiotherapy and investigated clinical and dosimetric predictors of radiation pneumonitis in lung cancer patients with ILD. A systematic search was carried out in PubMed, Medline, Embase and the Cochrane database for articles published between January 2000 and April 2021. Two authors independently screened eligible studies that met our predefined criteria. Studies were assessed for design and quality and a qualitative data synthesis was carried out. The search strategy resulted in 1750 articles. After two rounds of screening, 24 publications were included. The median overall incidence of grade ≥3 radiation pneumonitis was 19.7% (range 8–46%). The incidence was greater in conventional radical radiotherapy-treated patients (median 31.8%) compared with particle beam therapy- or stereotactic ablative radiotherapy-treated patients (median 12.5%). The median rate of grade 5 radiation pneumonitis was 11.9% (range 0–60%). The presence of ILD was an independent predictor of severe radiation pneumonitis. Severe radiation pneumonitis was more common in the presence of usual interstitial pneumonia (UIP) pattern or idiopathic pulmonary fibrosis (IPF) than non-UIP or non-IPF subtype. Several other clinical predictors were reported in the literature. V5, V10, V20 and mean lung dose were the most common dosimetric predictors for severe radiation pneumonitis, often with stricter dose constraints than conventionally used. Patients with lung cancer associated with ILD had a poorer overall survival compared with patients without ILD. In conclusion, patients with lung cancer associated with ILD have a poor prognosis. They are at high risk of severe and even fatal radiation pneumonitis. Careful patient selection is necessary, appropriate high-risk consenting and strict lung dose-volume constraints should be used, if these patients are to be treated with thoracic radiotherapy.Citation
Saha A, Dickinson P, Shrimali RK, Salem A, Agarwal S. Is Thoracic Radiotherapy an Absolute Contraindication for Treatment of Lung Cancer Patients With Interstitial Lung Disease? A Systematic Review [Internet]. Clinical Oncology. Elsevier BV; 2022.Journal
Clin Oncol (R Coll Radiol)DOI
10.1016/j.clon.2022.01.043PubMed ID
35168842Additional Links
https://dx.doi.org/10.1016/j.clon.2022.01.043Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.clon.2022.01.043
Scopus Count
Collections
Related articles
- Impact of Pretreatment Interstitial Lung Disease on Radiation Pneumonitis and Survival in Patients Treated With Lung Stereotactic Body Radiation Therapy (SBRT).
- Authors: Glick D, Lyen S, Kandel S, Shapera S, Le LW, Lindsay P, Wong O, Bezjak A, Brade A, Cho BCJ, Hope A, Sun A, Giuliani M
- Issue date: 2018 Mar
- Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy.
- Authors: Li F, Liu H, Wu H, Liang S, Xu Y
- Issue date: 2021 Apr 13
- Clinical and dosimetric predictors of radiation pneumonitis in early-stage lung cancer treated with Stereotactic Ablative radiotherapy (SABR) - An analysis of UK's largest cohort of lung SABR patients.
- Authors: Saha A, Beasley M, Hatton N, Dickinson P, Franks K, Clarke K, Jain P, Teo M, Murray P, Lilley J
- Issue date: 2021 Mar
- Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis.
- Authors: Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K, Narisada H, Korogi Y
- Issue date: 2013 Nov
- Carbon-ion radiotherapy for non-small cell lung cancer with interstitial lung disease: a retrospective analysis.
- Authors: Nakajima M, Yamamoto N, Hayashi K, Karube M, Ebner DK, Takahashi W, Anzai M, Tsushima K, Tada Y, Tatsumi K, Miyamoto T, Tsuji H, Fujisawa T, Kamada T
- Issue date: 2017 Sep 2